GlassScriptPhysician profile
Kerri Patton
NPI 1629435847
$7,033.53
in general payments reported to CMS, 2019-2025
44 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,534 · 2022: $1,265 · 2023: $1,354 · 2024: $1,203 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,234.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $970.89 | 2021-2025 | |
| Pfizer INC. | $779.00 | 2021-2025 | |
| Lilly USA, LLC | $744.68 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $622.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $421.86 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.26 | 2021-2025 | Jardiance, Spiriva Respimat |
| Glaxosmithkline, LLC. | $406.63 | 2021-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $321.00 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.06 | 2021-2024 | Xifaxan |
| Shield Therapeutics INC | $170.91 | 2024-2025 | |
| Corium, LLC | $131.76 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $129.08 | 2021-2023 | Trintellix |
| Aimmune Therapeutics, INC. | $127.31 | 2024-2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $119.55 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $113.86 | 2023-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.